The Cell Surface Glycoprotein CD200 Receptor 1 pipeline drugs market research report outlays comprehensive information on the Cell Surface Glycoprotein CD200 Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cell Surface Glycoprotein CD200 Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Dermatology, and Central Nervous System which include the indications Solid Tumor, Fallopian Tube Cancer, Autoimmune Disorders, Inflammation, Atopic Dermatitis (Atopic Eczema), and Dementia. It also reviews key players involved in Cell Surface Glycoprotein CD200 Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Cell Surface Glycoprotein CD200 Receptor 1 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 2, and 5 respectively.
Cell Surface Glycoprotein CD200 Receptor 1 overview
Cell surface transmembrane glycoprotein CD200 receptor 1 is a protein that in humans is encoded by a gene CD200R1. This is also known as OX-2 receptor and a member of the immunoglobulin superfamily. This receptor is restricted to the surfaces of myeloid lineage cells, CD4+ T cells and limits inflammation by inhibiting the expression of pro-inflammatory molecules. It interacts with CD200 transmembrane glycoprotein that can be expressed on variety of cells including neurons, epithelial cells endothelial cells, fibroblasts, and lymphoid cells.
For a complete picture of Cell Surface Glycoprotein CD200 Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
